{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:22:06Z","timestamp":1778260926253,"version":"3.51.4"},"reference-count":44,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T00:00:00Z","timestamp":1651968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030841","name":"Exact Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030841","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/13696998.2022.2066399","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T12:05:14Z","timestamp":1649851514000},"page":"591-604","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5743-2184","authenticated-orcid":false,"given":"Vladislav","family":"Berdunov","sequence":"first","affiliation":[{"name":"PHMR Ltd, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Millen","sequence":"additional","affiliation":[{"name":"Exact Sciences, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4070-9017","authenticated-orcid":false,"given":"Andrew","family":"Paramore","sequence":"additional","affiliation":[{"name":"Exact Sciences, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6015-7841","authenticated-orcid":false,"given":"Peter","family":"Hall","sequence":"additional","affiliation":[{"name":"Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Perren","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Brown","sequence":"additional","affiliation":[{"name":"PHMR Ltd, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Griffin","sequence":"additional","affiliation":[{"name":"Jane Griffin Associates, East Molesey, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Reynia","sequence":"additional","affiliation":[{"name":"Exact Sciences, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Fryer","sequence":"additional","affiliation":[{"name":"Exact Sciences, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Longworth","sequence":"additional","affiliation":[{"name":"PHMR Ltd, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,5,8]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70383-7"},{"key":"e_1_3_5_3_1","unstructured":"Early and locally advanced breast cancer: diagnosis and management NICE guideline [Internet]; 2018; [cited 2020 Aug 14]. Available from: www.nice.org.uk\/guidance\/ng101"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5524"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70314-6"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2464"},{"issue":"1","key":"e_1_3_5_7_1","first-page":"1","article-title":"Clinical outcomes in ER\u2009+\u2009HER2 -node-positive breast cancer patients who were treated according to the recurrence score results: evidence from a large prospectively designed registry","volume":"3","author":"Stemmer SM","year":"2017","unstructured":"Stemmer SM, Steiner M, Rizel S, et\u00a0al. Clinical outcomes in ER\u2009+\u2009HER2 -node-positive breast cancer patients who were treated according to the recurrence score results: evidence from a large prospectively designed registry. NPJ Breast Cancer. 2017;3(1):1\u20137.","journal-title":"NPJ Breast Cancer"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2012.09.003"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108873"},{"key":"e_1_3_5_10_1","unstructured":"Kalinsky K. Predicting chemotherapy benefit in node-positive breast cancer with the 21-gene test: the Oncotype DX Breast Recurrence Score\u00ae Test. San Antonio Breast Cancer Conference; 2021."},{"key":"e_1_3_5_11_1","unstructured":"National Institute for Health and Care Excellence. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. London (UK); 2018."},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7985"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.04.021"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta17440"},{"key":"e_1_3_5_15_1","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal [Internet]; 2013. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword"},{"key":"e_1_3_5_16_1","unstructured":"Curtis Lesley A Burns A. Unit costs of health and social care 2018. Project report. Canterbury (UK): University of Kent; 2018."},{"key":"e_1_3_5_17_1","unstructured":"Kalinsky K Barlow WE Gralow JR. Distant-disease free interval in participants with 1\u20133 positive lymph nodes hormone receptor-positive and HER2-negative breast cancer with recurrence score\u2009<\u2009or = 25 randomized to endocrine therapy +\/- chemotherapy: SWOG S1007 (RxPONDER). San Antonio (TX): San Antonio Breast Cancer Symposium; 2021."},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-0300-2"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2121-6"},{"key":"e_1_3_5_20_1","unstructured":"Office for National Statistics. National life tables 2016\u20132018 United Kingdom [Internet]; 2019; [cited 2021 Feb 3]. Available from: https:\/\/www.ons.gov.uk\/releases\/nationallifetablesuk2016to2018"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60740-6"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4782"},{"key":"e_1_3_5_23_1","unstructured":"National Institute for Health and Care Excellence. Liposomal cytarabine\u2013daunorubicin for untreated acute myeloid leukaemia. London (UK); 2018."},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-007-9202-8"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.06.019"},{"key":"e_1_3_5_26_1","unstructured":"National Institute for Health and Care Excellence. Azacitidine for the treatment of myelodysplastic syndromes chronic myelomonocytic leukaemia and acute myeloid leukaemia. London; 2011."},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00352.x"},{"key":"e_1_3_5_28_1","unstructured":"London Cancer Alliance West and South. LCA breast cancer clinical guidelines [Internet]; 2016; [cited 2022 Feb 18]. Available from: http:\/\/rmpartners.cancervanguard.nhs.uk\/wp-content\/uploads\/2017\/03\/lca-breast-cancer-clinical-guidelines-october-2013-updated-march-2016-.pdf"},{"key":"e_1_3_5_29_1","unstructured":"NHS Thames Valley. Chemotherapy regimens breast cancer [Internet]; 2022; [cited 2022 Feb 18]. Available from: http:\/\/tvscn.nhs.uk\/wp-content\/uploads\/2018\/12\/Breast-4.2-November-2018.pdf"},{"key":"e_1_3_5_30_1","unstructured":"London Cancer Alliance West and South. Breast pathway group FEC75 in early breast cancer [Internet]; 2016; [cited 2022 Feb 18]. Available from: https:\/\/rmpartners.nhs.uk\/wp-content\/uploads\/2017\/03\/LCA-Breast-FEC75-EBC-November-2014.pdf"},{"key":"e_1_3_5_31_1","unstructured":"London Cancer Alliance West and South. Breast pathway group \u2013 EC \u00d7 4 \u2013 Docetaxel \u00d7 4: epirubicin & cyclophosphamide followed by docetaxel in early breast cancer [Internet]; 2016; [cited 2022 Feb 18]. Available from: https:\/\/rmpartners.nhs.uk\/wp-content\/uploads\/2017\/03\/LCA-Breast-EC-Docetaxel-EBC-November-2014.pdf"},{"key":"e_1_3_5_32_1","unstructured":"Department of Health and Social Care. Drugs and pharmaceutical electronic market information tool (eMIT) [Internet]; 2021; [cited 2022 Jan 7]. Available from: https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit"},{"key":"e_1_3_5_33_1","unstructured":"National Institute for Health and Care Excellence. British National Formulary [Internet]; 2020; [cited 2022 Jan 7]. Available from: https:\/\/bnf.nice.org.uk\/"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2017.10.008"},{"key":"e_1_3_5_35_1","unstructured":"National Institute for Health and Care Excellence. Ribociclib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer [Internet]. London (UK); 2019. Available from: https:\/\/www.nice.org.uk\/guidance\/ta593"},{"key":"e_1_3_5_36_1","unstructured":"National Institute for Health and Care Excellence. Abemaciclib with an aromatase inhibitor for previously untreated hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer; 2019."},{"key":"e_1_3_5_37_1","unstructured":"National Institute for Health and Care Excellence. Palbociclib with an aromatase inhibitor for previously untreated hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer [Internet]; 2017. Available from: https:\/\/www.nice.org.uk\/guidance\/ta495"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603887"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2016.1112735"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlpt.2018.12.001"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4162-3"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.506"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e12002"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.5941"},{"key":"e_1_3_5_45_1","unstructured":"National Comprehensive Cancer Network. NCCN guidelines: breast cancer version 2.2021. Plymouth Meeting (PA); 2021."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2022.2066399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:21:00Z","timestamp":1729164060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2022.2066399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,8]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/13696998.2022.2066399"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2022.2066399","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-03-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}